PET in breast cancer

Flanagan, Fidelma; Dehdashti, Farrokh; Siegel, Barry A.

doi:10.1016/s0001-2998(98)80034-2

Cited by 92 publications

(64 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several clinical studies have shown that FDG-PET is both sensitive and specific for detecting primary breast cancers and for differentiating between breast cancer and benign lesions [1][2][3][4][5][6][7][8]. FDG-PET also has been used to evaluate tumor response to chemotherapy and hormone therapy [9][10][11].…”

mentioning

confidence: 99%

Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer

et al. 2001

View full text Add to dashboard Cite

Fluorodeoxyglucose-positron emission tomography (FDG-PET) is a noninvasive imaging technique capable of identifying primary tumors and metastases with high sensitivity and accuracy. The aim of this study was to evaluate the diagnostic accuracy of whole-body FDG-PET imaging for the detection of recurrent or metastatic breast cancer after surgery. Whole-body FDG-PET imaging was performed on 27 patients with suspected recurrent breast carcinoma. PET images were evaluated qualitatively for each patient and lesion. FDG-PET scans showed that there were 61 reference sites of malignant or benign lesions in 27 patients. In a patient-based analysis, FDG-PET scans correctly identified 16 of 17 patients with recurrent or metastatic disease and 8 of 10 without recurrence, resulting in a sensitivity, specificity, and accuracy of 94%, 80%, and 89%, respectively. In a lesion-based analysis, FDG-PET scans correctly identified 46 of 48 lesion sites with recurrent or metastatic disease and 11 of 13 without recurrence. The overall sensitivity, specificity, and accuracy for all lesion sites were 96%, 85%, and 93%, respectively. FDG-PET scans revealed unsuspected recurrent or metastatic diseases in 8 of 27 (30%) of patients and 11 of 20 (55%) distant metastatic lesions. In 13 patients treatment was altered by the outcome of the PET scan. We concluded that whole-body FDG-PET scan is a useful diagnostic imaging modality for detecting recurrent or metastatic breast carcinoma in patients suspected of having recurrent disease after primary surgery.

show abstract

mentioning

confidence: 99%

Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer

et al. 2001

View full text Add to dashboard Cite

show abstract

“…The radiopharmaceutical more common for that purpose is 18 F-FDG. 18 F-FDG has been evaluated for diagnosis, staging ( Figure 15) and restaging, monitoring therapy response and prognostication in patients with breast cancer [72]. Most studies evaluating 18 F-FDG to assess response to neoadjuvant therapy have measured change in 18 F-FDG uptake at mid-therapy, compared with at baseline, as a measure of response.…”

Section: Tomography Emission Positron/ Computed Tomography (Pet/ct)mentioning

confidence: 99%

Monitoring the Response to Neoadjuvant Chemotherapy in Breast Cancer

Koga¹,

Moriguchi²,

Uemura³

et al. 2013

Neoadjuvant Chemotherapy - Increasing Relevance in Cancer Management

View full text Add to dashboard Cite

“…F-fluorodeoxyglucose positron emission tomography (FDG PET) has been introduced as a method with a very high sensitivity and specificity for imaging the breast [105,106]. The reported sensitivity for FDG PET was found to be in the high range of 85-95% with a specificity ranging from 80% to 100% and a positive predictive value greater than 90% [106,107]. Secondary goals for PET are related to staging of axillary and internal lymph nodes, the detection of metastatic disease, the detection of local or distant recurrence, and the assessment of the response of the tumor to treatment.…”

Section: M Tc-sestamibi Scintimammography In Detecting Breast Cancermentioning

confidence: 99%

99mTc-Sestamibi Scintimammography

Bucerius

2011

99mTc-Sestamibi

View full text Add to dashboard Cite

From an anatomical point of view, the mammary gland is part of the female secondary sexual characteristics. The primary biological function of the mammary glands is the feeding of infants with breast milk. The mammary glands belong to the major glands of the cutis (glandulae cutis) and develop from epithelial cones, which grow in the surrounding connective tissue. Initially, the mammary glands are established in the same way in both genders.The female mammary glands are located on the major and minor pectoral muscles (M. pectoralis major, M. pectoralis minor) between the third and the seventh rib and between the sternal-and axillary line. The arterial blood supply of the mammary glands is provided by vascular branches (R. mammarii mediales and laterales) of the internal and lateral thoracic arteries (A. thoracica interna, A. thoracica lateralis) as well as by branches (R. preforantes and R. mammarii laterales) of the anterior and posterior intercostal arteries (Aa. intercostales anterior and posterior). The venous drain follows from superficial veins into the lateral and internal thoracic veins (Vv. thoracica lateralis and interna). The mammary glands are characterized by numerous lymphatic vessels, which build a superficial and deep lymphatic mesh with several directions of lymphatic drainage. From a clinical point of view, the main and most important lymphatic drainage reaches the axillary lymph nodes. Additional lymphatic drains flow off to the cervical lymph nodes superior to the clavicles and via the interpectoral lymphatic nodes (N. lymphatici interpectorales) between the pectoral muscles to the axillary lymph nodes, via the parasternal lymph nodes (N. lymphatici parasternales) along the internal thorac vein, and via the

show abstract

PET in breast cancer

Cited by 92 publications

References 37 publications

Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer

Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer

Monitoring the Response to Neoadjuvant Chemotherapy in Breast Cancer

99mTc-Sestamibi Scintimammography

Contact Info

Product

Resources

About